Fertility Preservation and Gonadotoxic-Therapy Counseling in Testicular Cancer
A 27-year-old man with elevated-risk stage I seminoma has days, not weeks, to choose between surveillance and adjuvant carboplatin — and a second, irreversible decision about fertility riding on the same compressed clock.
J.P., a 27-year-old man, got engaged four months ago and has spent most weekends since helping his fiancée's family renovate the house they plan to move into together, work he describes as the thing keeping his mind off the diagnosis that's interrupted every other part of the last two weeks. A self-detected testicular mass led to radical orchiectomy ten days ago, with pathology returning classic seminoma, clinical stage I, tumor size 4.2cm with lymphovascular invasion present and no invasion of the rete testis. Which of those features actually predicts relapse in seminoma is less settled than it looks. The risk factors that have guided adjuvant decisions for two decades are tumor size over 4cm and rete testis invasion, from Warde's pooled surveillance analysis; lymphovascular invasion is the established risk factor in nonseminomatous disease, and a systematic review of stage I seminoma surveillance found no association between it and relapse at all. It has re-entered the picture recently — Boormans' EAU risk model incorporates size, rete testis invasion and lymphovascular invasion together, and a Danish nationwide cohort found lymphovascular invasion an independent predictor. Under the EAU model J.P. carries two of three factors and sits in the intermediate band, roughly a twenty percent five-year relapse risk against eight percent for a man with none — but that model is recent, and the older scheme he is also often judged against would count him as having exactly one risk factor. Post-orchiectomy tumor markers have normalized, and staging CT shows no retroperitoneal or distant disease, which means every decision left in front of him is being made ahead of any visible evidence the cancer has or hasn't already spread.
The decision in front of him — surveillance versus a single adjuvant cycle of carboplatin at the guideline-recommended AUC 7 dose — has to happen on a compressed timeline, because seminoma is a fast-doubling tumor and delay itself carries real biological cost. But there is a second decision riding on the same clock that neither surveillance nor treatment resolves on its own: fertility. He and his fiancée want children, and while carboplatin is understood to carry meaningfully less gonadotoxicity than the multi-agent BEP regimen used for higher-stage disease, its effect on spermatogenesis is real and measurable, not negligible. Whatever oncologic strategy he chooses, sperm banking has to happen before any chemotherapy is given — and even choosing surveillance doesn't remove the question, since a later relapse could still mean treatment on a timeline that leaves even less room to bank than he has right now.
In clinic, two clocks running at once
Given his combination of tumor size over 4cm and lymphovascular invasion, I'd recommend a single adjuvant cycle of carboplatin at AUC 7 rather than surveillance. Under the EAU risk model that combination puts him in the intermediate band, around twenty percent at five years against eight percent with no risk factors — and I'll grant it's the newer model, and that the older size-plus-rete-testis scheme would score him lower. Carboplatin is the least gonadotoxic adjuvant option we have — meaningfully less toxic to spermatogenesis than the BEP regimen used for higher-stage disease. One low-toxicity cycle now, reducing relapse risk substantially, seems like a reasonable trade.
I'd recommend surveillance instead. Even with his risk features, the great majority of surveillance patients in his risk category never actually relapse — we'd be treating most men for a disease course that, for most of them individually, was never going to happen. If he does relapse, we treat then, with full BEP or a comparable regimen, and he's avoided gonadotoxic exposure entirely in the scenario — the majority scenario — where his cancer never comes back.
Carboplatin's toxicity being lower than BEP's doesn't make it zero, but it's a meaningfully smaller cost than what you're describing as the alternative. I don't think 'most men won't relapse' should outweigh a real, substantial relapse-risk reduction from a single low-toxicity cycle, particularly given how elevated his specific risk features actually are.
I want to step outside the surveillance-versus-treatment argument for a moment, because there's a decision underneath both of your positions that has to happen regardless of which oncologic path he chooses. Carboplatin's gonadotoxicity is real, not negligible, even at its lower relative burden compared to BEP — and if he chooses surveillance and later relapses, that relapse could come on a timeline that leaves him even less room to bank sperm than he has today. Either way, sperm banking needs to happen now, before any chemotherapy decision is finalized, not as an afterthought once the oncologic plan is set.
I'd also flag something specific to timing, and I want to state it precisely because it is easy to state backwards. Semen quality in men with testicular cancer is frequently already impaired at diagnosis, before any treatment — that is an argument for banking more than one sample, not for waiting. What waiting costs is different: sperm DNA damage after platinum chemotherapy is measurable and takes on the order of two years to return to baseline, so a sample banked after treatment starts is not equivalent to one banked before it. This doesn't resolve which of you is right about carboplatin versus surveillance — it just means neither answer should be finalized without banking happening first, and it can happen on a timeline of days, not weeks, without meaningfully delaying whichever path he chooses.
Agreed unanimously and without dispute: sperm banking scheduled within the next several days, before any chemotherapy decision is finalized. This resolved the one part of the discussion where the team had no disagreement.
Not agreed: whether to proceed with adjuvant carboplatin or surveillance. J.P. was given both positions in full, including the specific relapse-risk numbers behind each, and elected to take an additional week to discuss the decision with his fiancée before choosing, with sperm banking proceeding in parallel regardless of which path he settles on.